DE10252478A1 - Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester - Google Patents

Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester Download PDF

Info

Publication number
DE10252478A1
DE10252478A1 DE2002152478 DE10252478A DE10252478A1 DE 10252478 A1 DE10252478 A1 DE 10252478A1 DE 2002152478 DE2002152478 DE 2002152478 DE 10252478 A DE10252478 A DE 10252478A DE 10252478 A1 DE10252478 A1 DE 10252478A1
Authority
DE
Germany
Prior art keywords
syndrome
chronic fatigue
acid
derivative
tetradecenoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2002152478
Other languages
German (de)
Inventor
Klaus Dr. Med. Brill
Elmar W.J. Dr. Weiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEURONET INST fur HIRNFORSCHU
Neuronet Institut fur Hirnforschung & Angewandte Technologie GmbH
Original Assignee
NEURONET INST fur HIRNFORSCHU
Neuronet Institut fur Hirnforschung & Angewandte Technologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEURONET INST fur HIRNFORSCHU, Neuronet Institut fur Hirnforschung & Angewandte Technologie GmbH filed Critical NEURONET INST fur HIRNFORSCHU
Priority to DE2002152478 priority Critical patent/DE10252478A1/en
Publication of DE10252478A1 publication Critical patent/DE10252478A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Abstract

Use of tetradecenoic acid (14:1) (I) (and/or its derivatives) is claimed in the therapeutic treatment of fibromyalgia syndrome and chronic fatigue syndrome.

Description

Die Erfindung betrifft eine Verwendung von tetradecenoider Säure (14:1).The invention relates to a use of tetradecenoid acid (14: 1).

Tetradecenoide Säure oder myristolische Säure (14:1) ist zusammen mit Myristinsäure (14:0) Hauptbestandteil der in der Muskatnuß (Myristica Kombo) in Form von Triglyceriden enthaltenen Fettsäuremischung aus im wesentlichen Tetradecenomyristin, Laurodimyristin, Trimyristin, Myristoditetradecenoin, Laurotetradecenomyristin und Oleotetradecenomyristin.Tetradecenoid acid or myristolic acid (14: 1) is together with myristic acid (14: 0) main ingredient in the form of the nutmeg (Myristica combo) of fatty acid mixture containing triglycerides essentially Tetradecenomyrist, laurodimyrist, trimyrist, myristoditetradecenoin, Laurotetradecenomyrist and Oleotetradecenomyrist.

Es ist bekannt, ein mit Cetylalkohol umgeesterfes Extrakt aus der Muskatnuß als Nahrungsergänzungsmittel zu benutzen. Es verbessert den Stoffwechsel von Muskeln und Gelenken und fördert Beweglichkeit.It is known to use cetyl alcohol transesterifiable extract from nutmeg as a dietary supplement to use. It improves the metabolism of muscles and joints and promotes mobility.

Bekannt ist auch seit alters her, die Muskatnuß als Medizin gegen Rheuma und Geschwüre und zur Steigerung der Potenz zu benutzen.It has also been known since ancient times the nutmeg as Medicine for rheumatism and ulcers and use to increase potency.

Überraschend wurde jetzt gefunden, dass die tetradecenoide Säure und ihre Verbindungen zur erfolgreichen Behandlung von Fibromyalgiesyndrom und chronischem Müdigkeitssyndrom verwendet werden können.Surprised It has now been found that tetradecenoid acid and its compounds are successful Treatment of fibromyalgia syndrome and chronic fatigue syndrome can be used.

Eingesetzt wurde das oben bereits erwähnte Erzeugnis in der Darreichungsform von Kapseln. Eine Kapsel enthält 500 mg Fettsäurencetylester, davon etwa 24% Cetylester der tetradecenoiden Säure, 40 mg Dikalziumphosphat, 25 mg Maltodextrin, 25% Siliziumdioxid, 3 mg Mineralkomplex (Aulterrapulver) und 0,5 mg Magnesiumstearat.This has already been used above mentioned product in the dosage form of capsules. One capsule contains 500 mg Fettsäurencetylester, thereof approximately 24% cetylester of tetradecenoid acid, 40 mg dicalcium phosphate, 25 mg maltodextrin, 25% silicon dioxide, 3 mg mineral complex (egg rapeseed powder) and 0.5 mg magnesium stearate.

Die verabreichte Dosis betrug jeweils 1 bis 2 Kapseln pro Tag.The dose administered was in each case 1 to 2 capsules a day.

Es wurden bisher elf unter Fibromyalgiesyndrom leidende Patienten beiderlei Geschlechts im Alter zwischen 45 und 70 Jahren behandelt.So far there have been eleven under fibromyalgia syndrome suffering patients of both sexes between the ages of 45 and 70 years treated.

Bei acht Patienten stellten sich Besserungen der Beschwerden ein.In eight patients presented themselves Improvements in complaints.

Die Schmerzen verringerten sich. Schlaflosigkeit, Müdigkeit, Konzentrationsschwäche und Stimmungslabilität verringerten sich. Die körperliche Leistungsfähigkeit hatte wieder zugenommen.The pain subsided. Insomnia, fatigue, lack of concentration and mood instability decreased. The physical performance had increased again.

Bei drei Patienten blieb die Behandlung wirkungslos.Treatment remained in three patients ineffective.

Claims (4)

Verwendung von tetradecenoider Säure (14:1) und/oder mindestens einer Verbindung der tetradecenoiden Säure zur therapeutischen Behandlung von Fibromyalgiesyndrom oder chronischem Müdigkeitssyndrom.Use of tetradecenoid acid (14: 1) and / or at least one compound of the tetradecenoid acid therapeutic treatment of fibromyalgia syndrome or chronic Fatigue syndrome. Verwendung nach Anspruch 1 von Cetylester als der genannten Verbindung(en).Use according to claim 1 of cetylester than that mentioned connection (s). Verwendung nach Anspruch 1 oder 2, bei der die tetradecenoide Säure oder ihre Verbindungen) in Mischung mit anderen Fettsäuren oder deren Verbindungen vorliegen.Use according to claim 1 or 2, wherein the tetradecenoids Acid or their compounds) in a mixture with other fatty acids or their compounds available. Verwendung nach Anspruch 3 einer Mischung natürlichen Ursprungs, insbesondere einer aus einem Extrakt der Muskatnuß (Myristica Kombo) hergestellten Mischung.Use according to claim 3 of a mixture of natural Origin, especially one from an extract of nutmeg (Myristica Combo) prepared mixture.
DE2002152478 2002-11-12 2002-11-12 Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester Withdrawn DE10252478A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE2002152478 DE10252478A1 (en) 2002-11-12 2002-11-12 Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002152478 DE10252478A1 (en) 2002-11-12 2002-11-12 Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester

Publications (1)

Publication Number Publication Date
DE10252478A1 true DE10252478A1 (en) 2004-05-27

Family

ID=32185494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2002152478 Withdrawn DE10252478A1 (en) 2002-11-12 2002-11-12 Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester

Country Status (1)

Country Link
DE (1) DE10252478A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747452A4 (en) * 2018-02-01 2022-01-19 Korea Basic Science Institute Composition for improving physical strength or athletic ability, containing nutmeg extract as active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56154414A (en) * 1980-04-30 1981-11-30 Tsuruhara Seiyaku Kk Antiulcerative containing fatty acid or its derivative
JPH01106842A (en) * 1987-10-19 1989-04-24 Agency Of Ind Science & Technol 2-n-decyl-3-hydroxy-n-tetradecanoic acid and ester thereof
US20020039599A1 (en) * 1995-05-17 2002-04-04 Lin Henry C. Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56154414A (en) * 1980-04-30 1981-11-30 Tsuruhara Seiyaku Kk Antiulcerative containing fatty acid or its derivative
JPH01106842A (en) * 1987-10-19 1989-04-24 Agency Of Ind Science & Technol 2-n-decyl-3-hydroxy-n-tetradecanoic acid and ester thereof
US20020039599A1 (en) * 1995-05-17 2002-04-04 Lin Henry C. Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747452A4 (en) * 2018-02-01 2022-01-19 Korea Basic Science Institute Composition for improving physical strength or athletic ability, containing nutmeg extract as active ingredient

Similar Documents

Publication Publication Date Title
DE69822665T2 (en) USE OF 9-DESOXY-2 ', 9-ALPHA-METHANO-3-OXA-4,5,6-TRINOR-3,7- (1', 3'-INTERPHENYLENE) -13,14-DIHYDROPROSTAGLANDIN-F1 FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES
ATE357216T1 (en) FIBRATE-STATIN COMBINATIONS WITH REDUCED FOOD-DEPENDENT EFFECTS
JPH06128154A (en) Food composition
EP0203580A2 (en) Gamma-IFN as an agent for the inhibition (hindering) of the decay process of bones
WO2009065395A2 (en) Novel use of omega-3-fatty acid(s)
Anthony et al. Regulated effects of Capsicum frutescens supplemented diet (CFSD) on fasting blood glucose level, biochemical parameters and body weight in alloxan induced diabetic Wistar rats
JPS6377817A (en) Therapeutical composition, manufacture and therapy thereby
WO2020057029A1 (en) Compatible composition of masticinic acid and myrrh terpene, preparation method therefor, and use thereof
DE2113215A1 (en) Therapeutic compound
US5516801A (en) Fatty acid treatment for ectopic calcium deposition
DE2824165A1 (en) MEDICINAL PRODUCTS WITH ANTI-ANY ROSES AND ANTURAL NEUROSES-ELIMINATING EFFECT AND METHOD FOR PREPARING THE MEDICINAL PRODUCT
DE2359128A1 (en) MEDICINAL PRODUCTS BASED ON LISURIDE AND ITS PHYSIOLOGICALLY COMPATIBLE SALT
EP1796702B1 (en) Use of lavender oil for the prophylaxis and treatment of somatization disorders and posttraumatic stress disorder
EP0585027A1 (en) Use of fatty acids for treating abnormal tissue calcification
DE10252478A1 (en) Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester
DE60124516T3 (en) COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID
DE3431727A1 (en) Nasal spray for coryza and influenza with a content of zinc gluconate
CZ147894A3 (en) Pain inhibiting pharmacological preparation and process for preparing thereof
DE60007179T2 (en) Medicines containing pantothenic acid for the treatment of inflammatory joint diseases
DE60313785T2 (en) COMBINED USE OF MELATONIN AND METHYLPHENIDATE TO TREAT ATTENTION / HYPERACTIVITY DISORDERS.
DE4435352C2 (en) Use of a drug to treat AIDS
US20150352159A1 (en) Method and preparation for treating arthritis and arthrosis
Vuopala et al. Dimethyl Sulfoxide (DMSO) Ointment in the Treatment of Rheumatoid Arthritis: A Double Blind Study
DE69912383T2 (en) Medicinal products, in particular for dietetic use, containing pyruvic acid derivatives and an extract of the immature bitter orange
EP0358683A1 (en) Pharmaceutical substance

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8139 Disposal/non-payment of the annual fee